Osborne, W., Haynes, E., Wilson, W., Ediriwickrema, K., Paterson, J., Menne, T., El-Sharkawi, D., Chan, L. Y., Iyengar, S., Davies, A. J., Hiew, H. J., Kanfer, E., Foldes, D., Chaganti, S., Crosland, H., Owen, M., Follows, G., Santarsieri, A., Lawless, S., Wilson, M., McKay, P., Osborn, R., Tucker, D., Thiebaud, C. M., Fox, C. P., Ambrose, H., Gleeson, M., Lam, J., Broom, A., Smith, J., Wells, M., Oldham, L., Linton, K., Jeffers, L., Kuhnl, A., Collins, G., Qasim, J., Shah, N., McCulloch, R., Baloch, M., Cox, C., Lewis, D., Martin, A., Maw, K. Z. D., Norman, J., Deshani, V., Stables, V., Preston, G., Culligan, D., Willan, J., Ahearne, M., Motiwale, R., Dunning, L., Fawcett, J., Kelsey, P., Besley, C., Lugthart, S., Easton, J., Gurung, S., Ojie, D., Mathew, S., Auer, R. and Townsend, W. (2020) “Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2026.300569.